Pictured: ZiP C2 test instrument and assay testing for COVID-19.
Project Title: Establishing domestic capabilities for R&D and manufacture of point-of-care diagnostics
ZiP Diagnostics Pty Ltd (ZiP) aims to exploit the growing global market for point-of-care diagnostics for infectious diseases.
These include diseases of immediate national health concern, those that threaten regional health security, and those which are emerging threats. ZiP’s core technology is a novel nucleic acid amplification platform which will be used to develop point-of-care solutions for SARS-CoV-2, sexually transmissible infections (STI) gonorrhoea and chlamydia, hepatitis B and C, influenza, security sensitive biological agents and infections of global importance like malaria and tuberculosis.
ZiP has constructed is own ISO 13485 compliant manufacturing facility at Collingwood Victoria to manufacture and package point-of-care assays and will continue to conduct point-of-care diagnostics research at its R&D facility in Parkville Victoria.
ZiP leverages strong collaborative partnerships in industry and research. The company is a spin-off of Axxin Pty Ltd, which is a leading manufacturer of diagnostic point-of-care instruments, based in Fairfield, Victoria. ZiP will also leverage collaborative work with Burnet Institute, CSIRO, Victorian Infectious Diseases Reference Laboratory (VIDRL) and Foundation for Innovative New Diagnostics (FIND).
BMTH Round: Three
Project Partners: Axxin Pty Ltd, Burnett Institute, CSIRO, Victorian Infectious Diseases Reference Laboratory (VIDRL) and Foundation for Innovative New Diagnostics (FIND)
- MTPConnect Grant: $600,000
- Industry Contribution: $3,100,000
Duration: October 2020 - August 2022
Visit ZiP Diagnostics for more information | Twitter: @ZiPDiagnostics
Contact: Dr Jack Richards